Company
Gila Therapeutics, Inc.
Gila is pioneering a newly discovered biological pathway, the tongue-brain connection, to develop safer and more effective treatments for obesity and cardiometabolic disorders.
Also known as Gila Therapeutics
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- GILA THERAPEUTICS, INC.
Claim, correct or request removal
Record updated 28 September 2026
About
Gila Therapeutics is a clinical stage biotech company exploiting a novel, highly-targeted neural signaling system for the treatment of obesity, type 2 diabetes, and associated metabolic disorders.
Funding snapshot
- Total raised
- $5.7MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $400K2023-11-22
Funding rounds
- Round, 2023
- $400K2023-11-22, SEC form D sold, 7 investors
- Round, 2022
- $356K2022-11-15, SEC form D sold, 6 investors
- Round, 2021
- $1.2M2021-01-29, SEC form D sold, 28 investors
- Round, 2019
- $314K2019-03-04, SEC form D sold, 3 investors
- Round, 2017
- 2017-02-13
- Round, 2016
- $3.3M2016-04-15, SEC form D sold, 33 investors
Products
- Other
- Topical Lingual PYY
Loading relationship preview